Luzhu Biotech braces for make-or-break launch of shingles shot
The company has pared its annual losses but faces high costs and competitive challenges to deliver its voluntary vaccine into a tight market Key Takeaways: The biotech slashed its R&D…
CanSino looks for next growth shot in ‘life after Covid’
The vaccine maker is back to square one as a brief windfall fueled by demand for its Covid vaccines rapidly fades Key Takeaways: CanSino logged sizable asset impairments for its…
AIM Vaccine Shrinks Its IPO But Gives Chairman a Mega Paycheck
China’s second-largest maker of non-Covid vaccines has finally crossed the IPO finish line and will list its shares next Thursday Key Takeaways: AIM Vaccine is finally landing on the Hong…
RELATED ARTICLES
-
Meningitis shot delivers dose of good cheer for CanSino
688185.SHG -
China Merchants Bank falters as economic slowdown wipes out growth
600036.SHG
- Weihai Bank gets government-led year-end capital gift, highlighting its troubles
- Trip.com braces for new era of competition with anti-monopoly probe
- Eye drug maker VivaVision feels the strain in IPO funding dash
